A closer look at “FDA Approves Generic HIV Prevention Shot, Expanding Access for Lower-Income Countries”, exactly as the source publishes it. Food and Drug Administration has approved a generic version of a long-acting injectable HIV prevention drug, a move that could significantly lower costs and improve access in lower-income countries. The approval follows a push by global health organizations to make pre-exposure prophylaxis The approval follows a push by global health organizations to make pre-exposure prophylaxis (PrEP) more affordable and available outside high-income nations.
The generic version of the drug, which is administered every two months, has been shown to be highly effective at preventing HIV infection. By allowing generic manufacturing, the FDA decision enables procurement by major global health programs such as PEPFAR and the Global Fund, which supply medicines to countries with high HIV burdens. The full version stays on the original page, which this listing opens directly.